Effect of oestrogens on arterial physiology and mechanisms of its atheroprotective action in the animal;Effet des oestrogenes sur la physiologie arterielle et mecanismes de leur effet atheroprotecteur chez l'animal

Diabetes and Metabolism

Volumn 25, Issue SUPPL. 3, 1999, Pages 46-62

  Bayard, F ^a   Elhage, R ^b   Rami, J ^b   Maret, A ^b   Arnal, J F ^b  

^a CHU RANGUEIL   (France)

^b NONE

Author keywords

Arterial physiology; Atheroprotective effects; Atherosclerosis; Oestrogen receptor; Oestrogens

Indexed keywords

ENDOTHELIUM DERIVED RELAXING FACTOR; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; MEDROXYPROGESTERONE; NITRIC OXIDE; PHYTOESTROGEN; RECEPTOR SUBTYPE;

ADULT; ANIMAL CELL; ANIMAL TISSUE; ATHEROSCLEROSIS; CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG POTENTIATION; ENDOTHELIUM INJURY; FEMALE; HORMONAL REGULATION; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NONHUMAN; PATHOPHYSIOLOGY; VASODILATATION; ANIMAL; ARTERIOSCLEROSIS; ARTERY; DRUG EFFECT; PHYSIOLOGY; REVIEW; VASCULAR ENDOTHELIUM; VASOCONSTRICTION;

ANIMALS; ARTERIES; ARTERIOSCLEROSIS; ENDOTHELIUM, VASCULAR; ESTROGENS; RECEPTORS, ESTROGEN; VASOCONSTRICTION; VASODILATION;

EID: 0033142970     PISSN: 03381684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (58)

1. Grodstein F, et al. Postmenopausal hormone therapy and mortality [see comments]. N Engl J Med, 1997, 336, 1769-1775.
2. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA, 1998, 280, 605-613.
3. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, Tyroler HA, Rifkind BM. Cardiovascular mortality and noncontraceptive estrogen use in women : results from the Lipid Research Clinic's Program Follow-up Study. Circulation, 1987, 75, 1102-1109.
4. Renoir JM, Pahl A, Keller U, Baulieu EE. Immunological identification of a 50 kDa Mr FK506-binding immunophilin as a component of the non-DNA binding, hsp90 and hsp70 containing, heterooligomeric form of the chick oviduct progesterone receptor. C R Acad Sci III, 1993, 316, 1410-1416.
5. Janknecht R, Hunter T. Transcription. A growing coactivator network Nature, 1996, 383, 22-23.
6. Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA, 1996, 93, 5925-5930.
7. Losordo DW, Kearney M, Kim EA, Jekanowski J, Isner JM. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation, 1994, 89, 1501-1510.
8. Miller VM, Vanhoutte PM. 17β-estradiol augments endothelium-dependent contractions to arachidonic acid in rabbit aorta. Am J Physiol, 1990, 258, R1502-R1507.
9. Cheng DY, Gruetter CA. Chronic estrogen alters contractile responsiveness to angiotensin II and norepinephrine in female rat aorta. Eur J Pharmacol, 1992, 215, 171-176.
10. Barbacanne MA, Rami J, Michel JB, Philippe M, Souchard JP, Besombes JP, Bayard F, Arnal JF. Estradiol decreases endothelium-derived superoxide anion in rat aorta. Effect on NO bioactivity and peroxynitrite production. Cardiovasc Res, 1988, 41, 672-681.
11. Gisclard V, Miller VM, Vanhoutte P. Effect of 17β-estradiol on endothelium-dependent responses in the rabbit. J Pharmacol Exp Ther, 1988, 244, 19-22.
12. White MM, Zamudio S, Stevens T, Tyler R, Lindenfeld J, Leslie K, Moore LG. Estrogens, progesterone, and vascular reactivity : potential cellular mechanisms. Endocrine Rev, 1995, 16, 739-751.
13. Arnal JF, Clamens S, Pechet C, Nègre-Salvayre A, Allera C, Girolami JP, Salvayre R, Bayard F. Ethinylestradiol does not enhance the expression of nitric oxide synthase in bovine aortic endothelial cells but increases the release of bioactive nitric oxide by inhibiting superoxide anion production. Proc Natl Acad Sci USA, 1996, 93, 4108-4113.
14. Weiner CP, Martinez E, Zhu LK, Ghodsi A, Chestnut D. In vitro release of endothelium-derived relaxing factor by acetylcholine is increased during guinea pig pregnancy. Am J Obstet Gynecol, 1989, 161, 1599-1605.
15. Nadaud S, Philippe M, Arnal JF, Michel JB, Soubrier F. Sustained induction of aortic endothelial nitric oxide synthase expression in vivo in a model of chronic high flow. Circ Res, 1996, 79, 857-863.
16. Weiner CP, Lizasoain I, Baylis SA, Knowles RG, Charles IG, Moncada S. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci USA, 1994, 91, 5212-5216.
17. Xu DL, Martin PY, StJohn J, Tsai P, Summer SN, Ohara M, Kim JK, Schrier RW. Upregulation of endothelial and neuronal constitutive nitric oxide synthase in pregnant rats. Am J Physiol, 1996, 271, R1739-R1745.
18. Wang X, Barber D, Lewis D, McGregor C, Sleck G, Fitzpatrick L, Miller V. Gender and transcritional regulation of NO synthase and ET-1 in porcine aortic endothelial cells. Am J Physiol, 1997, 273, H1962-H1967.
19. Lantin-Hermoso R, Rosenfeld C, Yuhanna I, German Z, Chen Z, Shaul P. Estrogen acutely stimulates NO synthase activity in fetal pulmonary artery endothelium. Am J Physiol, 1997, 273, L119-L126.
20. MacRitchie A, Jun S, Chen Z, German Z, Yuhanna I, Sherman T, Shaul P. Estrogen upregulates endothelial NO synthase expression in fetal pulmonary endothelium. Circ Res, 1997, 81, 355-362.
21. Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W, Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD, Wissler RW. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis - A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation, 1994, 89, 2462-2478.
22. Elhage R, Arnal JF, Pierragi MT, Duverger N, Fiévet C, Faye JC, Bayard F. Estradiol-17β prevents fatty streak formation in apolipoprotein E-deficient mice. Arterioscl Thromb Vasc Biol, 1997, 17, 2679-2684.
23. Hough IL, Zilversmit DB. Effect of 17β-estradiol on aortic cholesterol content and metabolism in cholesterol-fed rabbits. Arteriosclerosis, 1986, 6, 57-63.
24. Adams MR, Kaplan JR, Manuck SB, Koritnik DR, Parks JS, Wolfe MS, Clarkson TB. Inhibition of coronary artery atherosclerosis by 17β-estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis, 1990, 10, 1051-1057.
25. Wagner JD, Clarkson TB, St Clair RW, Schwenke DC, Shively CA, Adams MR. Estrogen and progesterone replacement therapy reduces LDL accumulation in the coronary arteries of surgically postmenopausal cynomolgus monkeys. J Clin Invest, 1991, 88, 1995-2002.
26. Hayashi T, Fukuto JM, Ignarro LJ, Chaudhuri G. Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits : implications for atherosclerosis. Proc Natl Acad Sci USA, 1992, 89, 11259-11263.
27. Bell DR, Rensberger HJ, Koritnik DR, Koshy A. Estrogen pretreatment directly potentiates endothelium-dependent vasorelaxation of porcine coronary arteries. Am J Physiol, 1995, 37, H377-H383.
28. Plump AS, Smith JD, Hayek T. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficientmice created by homologousrecombination in ES cells. Cell, 1992, 71, 343-353.
29. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science, 1992, 258, 468-471.
30. Bourassa PA, Milos PM, Gaynor BJ, Breslow JL, Aiello RJ. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA, 1996, 93, 10022-10027.
31. Holm P, Korsgaard N, Shalmi M, Andersen HL, Hougaard P, Skouby SO, Stender S. Significant reduction of the antiatherogenic effect of estrogen by long-term inhibition of nitric oxide synthesis in cholesterol-clamped rabbits. J Clin Invest, 1997, 100, 821-828.
32. Elhage R, Bayard F, Richard V, Holvoet P, Duverger N, Fiévet C, Arnal JF. The prevention of fatty streak formation of 17ß-estradiol is not mediatedby the production of nitric oxide in apolipoprotein E-deficient mice. Circulation, 1997, 96, 3048-3052.
33. Liao F, Andalibi A, Qiao JH, Allayee H, Fogelman AM, Lusis AJ. Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction, and aortic fatty streak formation in mice. J Clin Invest, 1994, 94, 877-884.
34. Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci USA, 1995, 92, 8264-8268.
35. Olsen NJ, Kovacs WJ. Gonadal steroids and immunity. Endocrine Rev, 1996, 17, 369-384.
36. Deshpande R, Khalili H, Pergolizzi RG, Michael SD, Chang MY. Estradiol down-regulates LPS-induced cytokine production and NFkB activation in murine macrophages. Am J Reprod Immunol, 1997, 38, 46-54.
37. Frazier-Jessen MR, Kovacs EJ. Estrogen modulation of JE/monocyte chemoattractant protein-1 mRNA expression in murine macrophages. J Immunol, 1995, 154, 1838-1845.
38. Verbeuren TJ, Jordaens FH, Zonnekeyn LL, Van Hove CE, Coene MC, Herman AG. Effect of hypercholesterolemia on vascular reactivity in the rabbit. Circ Res, 1986, 58, 552-564.
39. Harrison D. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest, 1997, 100, 2153-2157.
40. Miyagawa K, Rosch J, Stanczyk F, Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nature Med, 1997, 3, 324-327.
41. Node K, Kitakaze M, Kosaka H, Minamino T, Sato H, Kuzuya T, Hori M. Roles of NO and Ca2 + -activated K + channels in coronary vasodilation induced by 17β-estradiol in ischemic heart failure. FASEB J, 1997, 11, 793-799.
42. Rosano GM, Sarrel PM, Poole-Wilson PA, Collins P. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet, 1993, 342, 133-136.
43. Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon RO. Effects of estrogen replacement therapy on peripheral vasomotor function in postmenopausal women. Am J Cardiol, 1995, 75, 264-268.
44. Chang E, Harley CB. Telomere length and replicative aging in human vascular tissues. Proc Natl Acad Sci USA, 1995, 92, 11190-11194.
45. Spyridopoulos I, Sullivan A, Kearney M, Isner J, Losordo D. Estrogen-receptor-mediated inhibitio of human endothelial cell apoptosis. Circulation, 1997, 95, 1505-1514.
46. Krasinski K, Spyridopoulos I, Asahara T, van der Zee R, Isner JM, Losordo DW. Estradiol accelerates functional endothelial recovery after arterial injury. Circulation, 1997, 95, 1768-1772.
47. Iafrati M, Karas R, Aronovitz M, et al. Estrogen inhibits the vascular injury response in estrogen receptor a-deficient mice. Nature Med, 1997, 3, 545-548.
48. O'Brien JE, Peterson ED, Keeler GP, Berdan LG, Ohman EM, Faxon DP, Jacobs AK, Topol EJ, Califf RM. Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. J Am Coll Cardiol, 1996, 28 1111-1118.
49. Holm P, Andersen H, Nordestgaard B, Hansen B, Kjeldsen K, Slender S. Effect of oestrogen replacement on development of experimental arteriosclerosis : a study in transplanted and balloon-injured rabbit aortas. Atherosclerosis, 1995, 115, 191-200.
50. Holm P, Shalmi M, Korsgaard N, Guldhammer B, Skouby S, Slender S. A partial estrogen receptor agonist with strong antiatherogenic properties without noticeable effect on reproductive tissue in cholesterol-fed female and male rabbits. Arterioscl Thromb Vasc Biol, 1997, 17, 2264-2272.
51. Grese TA, et al. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci USA, 1997, 94, 14105-14110.
52. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, Scanlan TS. Differential ligand activation of estrogen receptors ERalpha and ERbeta at API sites [see comments]. Science, 1997, 277, 1508-1510.
53. Jordan VC. Long-term tamoxifen therapy to control or to prevent breast cancer : laboratory concept to clinical trials. Prog Clin Biol Res, 1988, 262, 105-123.
54. Grainger DJ, Metcalfe JC. Tamoxifen : teaching an old drug new tricks ? Nature Med, 1997, 2, 381-385.
55. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR, et al. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest, 1994, 93, 63-69.
56. Clarkson T, Anthony M, CP. J. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys [see comments]. J Clin Endocrinol Metab, 1998, 83, 721-726.
57. Tham D, Garner C, Haskell W. Potential health benefits of dietary phytoestrogens : a review of the clinical, epidemiological and mechanistic evidence. J Clin Endocr Metab, 1998, 83, 2223-2235.
58. Anthony M, Clarkson T, Bullock B, Wagner J. Soy protein versus soy phytoestrogens in the prevention of diet-induced coronary artery atherosclerosis of male cynomolgus monkeys. Arterioscler Thromb Vasc Biol, 1997, 17, 2524-2531.